Blog

The below Parliamentary question was asked by Carolyn Harris on 2015-11-23.

To ask the Secretary of State for Health, whether his Department’s Accelerated Access Review will consider issues relating to the routine availability of off-patent, repurposed drugs.

George Freeman

The Accelerated Access Review (AAR), chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for National Health Service patients to innovative medicines and medical technologies making our country the best place in the world to design, develop and deploy these products. The terms of the reference for the review focus on faster access to innovations, which may include certain off-patent repurposed drugs, as opposed to the routine availability of medicines or medical technologies.

Prior to establishing the terms of reference for the AAR, the Department reviewed evaluation reports and met with officials from previous initiatives on the uptake of innovation in the NHS including the Innovation, Health and Wealth report. As a result, building upon the lessons of previous reviews is explicit with the terms of reference of the AAR.

The AAR has regular meetings with senior officials from NHS England via a steering group as recommendations are being developed. In addition, some staff from NHS England have been assigned to support the review team.

Sir Hugh is still in the process of developing final recommendations which will be published in spring 2016. In his Interim Report published in October, Sir Hugh sets out a proposition on “galvanising the NHS”. This involves supporting the NHS to adopt innovation, more rapidly through better practical support, stronger incentives and the potential streamlining of local structures.

The Department reviewed evaluation reports and met with officials from previous initiatives on the uptake of innovation in the NHS prior to establishing the terms of reference for the AAR. It was clear that whilst progress has been made on the uptake of innovation in the NHS there is still much to do. Sir Hugh and the head of the External Advisory Group, Professor Sir John Bell, set out the case for uptake of innovation in the recently published AAR Interim Report.

The AAR has senior level contact with officials working on Lord Carter’s review of NHS efficiency to ensure that information is shared between the two teams.

The below Parliamentary question was asked by Carolyn Harris on 2015-11-23.

To ask the Secretary of State for Health, what steps his Department has taken in the last 12 months to improve access to off-patent, repurposed drugs; and what assessment it has made of the effectiveness of those steps.

George Freeman

Our policy on generic prescribing has been in place for a number of years. The policy helps ensure that patients can access the medicine that best meets their needs and it has been a key driver in the National Health Service making maximum use of off-patent drugs which are also known as generics. We have the best prescribing rate for these drugs in Europe.

To support clinicians who may want to prescribe a product off-label for a patient to and improve the flow of research evidence into clinical practice, the Department hosted a Roundtable Event in February 2015. Attendees included the National Institute for Health and Care Excellence, Medicines and Healthcare products Regulatory Agency, Breast Cancer Now and other charities and discussions helped determine those non-legislative measures that could be undertaken. The Government is committed to this work and is holding a further roundtable event with charities.